Mother to Child Transmission at Birth · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission at Birth compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Mother to Child Transmission at 1 Month · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission at 1 Month compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Mother to Child Transmission Cumulative by 7 Months · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31
It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission Cumulative by 7 Months compared with AZT (+/‐ single dose NVP) (very low certainty).
1 finding from 1 review
Adequate pain relief as reported by women · women with perineal pain in the early postpartum period
NSAID may leads to higher adequate pain relief(4 hours after administration) compared with placebo (low certainty).
2 findings from 1 review
Need for additional analgesia (4 hours after administration) · women with perineal pain in the early postpartum period
NSAID probably leads to lower need for additional analgesia(4 hours after administration) compared with placebo (moderate certainty).
1 finding from 1 review
Need for additional analgesia (6 hours after administration) · women with perineal pain in the early postpartum period
It is very uncertain whether NSAID changes need for additional analgesia (6 hours after administration) compared with placebo (very low certainty).
1 finding from 1 review
Maternal drug adverse effects(4 hours after administration) · women with perineal pain in the early postpartum period
1 finding from 1 review
Maternal drug adverse effects (6 hours after administration) · women with perineal pain in the early postpartum period
NSAID showed no clear difference in maternal drug adverse effects(6 hours after administration) compared with placebo (low certainty).
1 finding from 1 review
Neonatal drug adverse effects · women with perineal pain in the early postpartum period
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival (OS) · People with advanced non‐small cell lung cancer
Combined immune checkpoint inhibitors (ICIs) probably leads to lower overall Survival (OS) compared with chemotherapy (moderate certainty).
1 finding from 1 review
Progression‐free survival · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall response rate (OSR) · People with advanced non‐small cell lung cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Grades 3 and 4 adverse events · People with advanced non‐small cell lung cancer
Combined immune checkpoint inhibitors (ICIs) showed no clear difference in adverse Events grade 3 to 4 compared with chemotherapy (low certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
It is very uncertain whether intravenous ketorolac changes number of participants with at least 50% pain relief over 4 hours compared with placebo (very low certainty).
1 finding from 1 review
Number of women requiring rescue medication · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
It is very uncertain whether intravenous ketorolac changes number of participants using rescue medication over 4 or 6 hours… compared with another NSAID (very low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
Intravenous ketorolac showed no clear difference in number of participants reporting any adverse event compared with another NSAID (moderate certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
Intravenous ketorolac showed no clear difference in number of participants experiencing a serious adverse event compared with another NSAID (low certainty).
1 finding from 1 review
Relief of pain · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
Intravenous ketorolac may leads to higher number of participants with at least 50% pain relief over 6 hours compared with placebo (low certainty).
1 finding from 1 review
Median (mean) time to use of rescue medication · adults (mean study ages 23 to 67 years) with acute postoperative pain after abdominal/pelvic, dental or orthopedic surgeries
1 finding from 1 review